Partner Content Partner Content Immuno-Oncology: A 360° View in NYC this February The Conference Forum has announced that the 3rd annual
News BMS and PsiOxus to collaborate on cancer-targeting armed vir... BMS to pay up to $936m for NG-348.
News AZ stakes its claim in immunotherapy with bladder cancer fil... After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 drug durvalumab .
News Avelumab filed, Pfizer and Merck prepare to join immunothera... Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market
News Scotland to fund BMS skin cancer combo Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
News BMS' Opdivo still streets ahead of Merck rival BMS to refocus operations, according to Q3 results.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
